Physician

Travis D Archuleta, MD

According to 2025 Medicare claims, Travis Archuleta, MD (NPI: 1457335010) practices hematology/oncology in the Pueblo, CO market, with the plurality of this provider's patient population coming from Pueblo, CO. This provider's primary affiliated billing organization is ROCKY MOUNTAIN CANCER CENTERS LLP (NPI: 1518941186; TIN: 841457488) and primary practice location at 81003-9998. Archuleta is affiliated with the Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Archuleta's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 509 traditional Medicare patients, billed 125,885 HCPCS/CPT codes, and received $2,248,478 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,707 prescription claims across 324 beneficiaries totaling $3,442,914 in drug costs, led by Revlimid (Lenalidomide). DME data shows 100 claims. Open Payments data shows 2 records totaling $76. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,581,140 to $2,248,478. Similarly, Part D prescription costs have risen steadily, from $1,660,216 to $3,442,914. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	933	136,554	$1,581,140
2016	937	116,801	$1,681,612
2017	933	134,816	$1,976,711
2018	869	154,275	$2,396,876
2019	724	157,057	$2,074,124
2020	655	147,349	$2,144,516
2021	598	143,417	$2,085,371
2022	552	140,625	$2,016,755
2023	532	161,913	$2,757,113
2024	509	125,885	$2,248,478

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	221	1,210	$1,660,216
2016	229	1,234	$2,279,232
2017	231	1,329	$3,019,258
2018	230	1,375	$2,723,070
2019	247	1,349	$3,026,020
2020	255	1,387	$3,397,091
2021	267	1,503	$4,366,514
2022	286	1,561	$4,416,754
2023	298	1,493	$4,088,636
2024	324	1,707	$3,442,914

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	22	139	$69,063
2016	N/R	115	$39,445
2017	31	150	$33,382
2018	N/R	50	$9,416
2019	N/R	46	$6,650
2020	12	71	$6,615
2021	24	84	$6,053
2022	N/R	53	$1,686
2023	N/R	42	$2,849
2024	23	100	$2,388

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	142	371	$96
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	175	298	$66
80053	Blood test, comprehensive group of blood chemicals	142	463	$10
36415	Insertion of needle into vein for collection of blood sample	214	782	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	183	691	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	63	1,722	$1,219,430
Pomalyst	Pomalidomide	15	399	$285,105
Lenalidomide	Lenalidomide	22	616	$273,479
Calquence	Acalabrutinib Maleate	16	480	$243,118
Ibrance	Palbociclib	14	392	$229,540

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	11	34	$1,359
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	12	38	$715
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	17	$201
J8530	Cyclophosphamide; oral, 25 mg	N	N/R	11	$113

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$76	Tempus AI, Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Travis D. Archuleta, MD?

Tedicare shows public-source Medicare data for Travis D. Archuleta, MD (NPI 1457335010), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Travis D. Archuleta, MD have ACO affiliation data?

Travis D. Archuleta, MD is shown with ACO affiliation data for Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Travis D. Archuleta, MD?

Travis D. Archuleta, MD is linked to ROCKY MOUNTAIN CANCER CENTERS LLP (billing NPI 1518941186) in the available physician profile data.

Does Travis D. Archuleta, MD have Open Payments data?

Travis D. Archuleta, MD has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.